February 3, 2006 – Earlier this week, Iomai completed its IPO, one of four biotech companies to do so in the past two weeks. Like other companies this week, it had to accept lower terms that it originally proposed, and it is trading below its IPO price. Iomai has a proprietary patch technology called transcutaneous immunization (TCI), which it uses to deliver vaccines and immunostimulants. We look at the finances and the products in development at Iomai...
